A Novel Bispecific Nanobody Targeting PDCD1 and TNFRSF4 for Next-Generation Cancer Immunotherapy

VHH-P546 is a humanized nanobody-based bispecific antibody that simultaneously targets programmed cell death 1 (PDCD1) and TNF receptor superfamily member 4 (TNFRSF4). Currently in the biological testing stage of development, VHH-P546 is engineered for advanced cancer therapy. By engaging both PDCD1 and TNFRSF4, this molecule is designed to modulate key immune checkpoints and provide a multifaceted approach to tumor immunomodulation. The dual-targeting mechanism addresses pathways involved in immune evasion and activation, offering potential benefits over monospecific immunotherapies. With an innovative design and expression in HEK293 cells, VHH-P546 represents a promising step forward in cancer immunotherapy.

Licensing Opportunity

VHH-P546 is available for global out-licensing and co-development partnerships. We welcome inquiries from biopharmaceutical partners interested in advancing this innovative dual-target cancer immunotherapy program.

Development Phase

Modality

VHH-P546 features a bispecific IgG_HC-VH tetravalent symmetrical architecture, integrating an anti-PDCD1 fragment antigen-binding region, a mutated IgG1 Fc domain, and an anti-TNFRSF4 heavy chain variable domain. As a nanobody, VHH-P546 capitalizes on the small size and single-domain properties inherent to this modality, providing enhanced tissue penetration, increased stability, and accessibility to challenging epitopes within the tumor microenvironment. The tetravalent symmetrical configuration supports strong avidity and effective immune engagement, while the use of a mutated Fc domain holds promise for optimized effector functions. Collectively, these attributes enhance the biotherapeutic potential of VHH-P546 for cancer therapy.

Target

PDCD1 and TNFRSF4 are pivotal immune checkpoint molecules relevant to the regulation of T-cell activity in cancer. PDCD1, a cell-surface receptor primarily expressed on activated T cells, functions as a negative regulator of immune responses, curbing T-cell activity within the tumor microenvironment. TNFRSF4, also known as a co-stimulatory receptor, is expressed on activated T cells and other immune subsets, serving as an amplifier of immune activation. Targeting both PDCD1 and TNFRSF4 allows VHH-P546 to inhibit immune suppression while concurrently enhancing immune cell activation against cancer cells. The strategic combination of PDCD1 and TNFRSF4 offers a robust approach to overcoming immune resistance and optimizing antitumor immunity, highlighting the value of dual checkpoint targeting in contemporary oncology drug development.

Mechanism of Action

VHH-P546 exerts its therapeutic activity by selectively binding to PDCD1 and TNFRSF4, acting as a dual immune checkpoint inhibitor and modulator of signal transduction. Targeting PDCD1 disrupts the inhibitory signaling that restrains T-cell mediated antitumor immunity, while engagement of TNFRSF4 delivers potent co-stimulatory signals to enhance T-cell activation and proliferation. By simultaneously opposing immune suppression and promoting immune activation, VHH-P546 advances a synergistic approach to restoring effective antitumor responses. Furthermore, the nanobody scaffold of VHH-P546 provides a versatile platform for the development of advanced constructs, such as antibody-drug conjugates and multivalent bispecifics, thereby expanding its therapeutic reach.

Cancer

Cancer encompasses a wide range of diseases characterized by unregulated cell proliferation and the potential for invasion or metastasis. It is a leading cause of mortality worldwide, with millions of new cases diagnosed annually. Treatment modalities such as surgery, chemotherapy, radiation therapy, and targeted therapies have expanded significantly, yet many patients face significant challenges related to resistance, toxicity, and relapse. Immunotherapy has emerged as a transformative approach, but limitations persist, including incomplete tumor eradication and immune escape. There is a continued need for innovative therapies that can address these challenges. VHH-P546, by targeting both PDCD1 and TNFRSF4, offers a novel immunotherapeutic strategy with the potential to overcome immune resistance and improve outcomes for patients with various forms of cancer.